Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
BMC Veterinary Research|February 2, 2020
Acute tea tree oil intoxication in a pet cockatiel (Nymphicus hollandicus): a case reportAlessandro Vetere, Mara Bertocchi, Igor Pelizzone, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 18, 2026
Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in ItalyPiero Barbanti, Cristina Tassorelli, Fabrizio Vernieri, et al.
Neurosurgical Focus|July 1, 2021
Mechanical thrombectomy in acute ischemic stroke with tandem occlusions: impact of extracranial carotid lesion etiology on endovascular management and outcomeValerio Da Ros, Jacopo Scaggiante, Francesca Pitocchi, et al.
European Journal of Neurology|September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT studyFabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
The Journal of Headache and Pain|November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
European Radiology|March 9, 2021
The role of the deep convolutional neural network as an aid to interpreting brain [18F]DOPA PET/CT in the diagnosis of Parkinson's diseaseArnoldo Piccardo, Roberto Cappuccio, Gianluca Bottoni, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
The Journal of Headache and Pain|March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 studyPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Pageof 6